+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antimicrobial Susceptibility Testing Market, by Product, Method, Application, End User - Forecast to 2028

  • PDF Icon

    Report

  • 104 Pages
  • August 2021
  • Region: Global
  • Meticulous Market Research Pvt. Ltd.
  • ID: 4991312
Antimicrobial Susceptibility Testing Market by Product (Manual {Susceptibility Discs, Plates, MIC Strips}, Consumables, Automated), Method (Diffusion, Dilution), Application (Clinical Diagnostics), End User (Hospitals, Pharma, Institutes) - Forecast to 2028



The global antimicrobial susceptibility testing market is expected to grow at a CAGR of 6.4% from 2021 to 2028 to reach $5.99 billion by 2028.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The antimicrobial susceptibility testing market's growth is mainly attributed to growth in infectious diseases, development of automated AST products, the emergence of multidrug resistance, increased funding and government initiatives for AMR and technological advancements, and new product developments. Active R&D to develop rapid antimicrobial susceptibility testing and growth prospects in emerging markets are offering market opportunities.

Based on product, the manual AST products segment is estimated to account for the largest share of the market in 2021. Higher adoption of manual techniques compared to automated due to their cost-effectiveness and ease of processing is a key factor supporting market growth. Further manual AST products are segmented into susceptibility discs, susceptibility plates, and minimum inhibitory concentration (MIC) test strips. Based on the type of manual AST products, the susceptibility discs segment is estimated to account for the largest share of the market in 2021.

Based on method, the automated AST products segment is expected to create several opportunities for market growth. The key factor attributing to the market growth is the emerging need to obtain the same-day antimicrobial susceptibility testing results to determine the treatment of a wide range of infectious diseases. Automated AST provides streamlined workflows and quantitative results. Further, accurate and precise measurements and enhanced performance offered by automated AST also support market growth.

Based on application, the clinical diagnostics segment is expected to account for the largest share of the antimicrobial susceptibility testing market in 2021 due to the rising burden of antimicrobial resistance and growing awareness about the use of antimicrobial susceptibility testing methods.

An in-depth analysis of the geographical scenario of the antimicrobial susceptibility testing (blood samples) market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is estimated to command the largest share of the global antimicrobial susceptibility testing market in 2021, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Rising antibiotic resistance and increasing government initiatives to fight antibiotic resistance are the major factors driving the growth of the antimicrobial susceptibility testing (blood sample) market in North America. Further, the increased prevalence of potentially fatal bloodstream infections caused by antimicrobial-resistant organisms also positively impacts the market growth.

Some of the key players operating in the global antimicrobial susceptibility testing market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), HiMedia Laboratories Pvt. Ltd. (India), MERLIN Diagnostika GmbH (Germany), Accelerate Diagnostics, Inc. (U.S.), Alifax S.r.l. (Italy), Creative Diagnostics (U.S.), Synbiosis (U.K.), and Zhuhai DL Biotech Co., Ltd (China).

Scope of the Report:


Global Antimicrobial Susceptibility Testing Market, by Product

  • Manual Antimicrobial Susceptibility Testing Products
  • Susceptibility Discs
  • Susceptibility Plates
  • Minimum Inhibitory Concentration (MIC) Strips
  • Consumables
  • Automated Antimicrobial Susceptibility Testing Products

Global Antimicrobial Susceptibility Testing Market, by Method

  • Disc Diffusion
  • Automated AST
  • Dilution
  • Other Methods
Other methods include Etest, genotypic methods, and MALDI-TOF MS.

Global Antimicrobial Susceptibility Testing Market, by Application

  • Clinical Diagnostics
  • Drug Discovery and Development
  • Other Applications
Other applications include epidemiology, veterinary diagnostic, and environmental monitoring

Global Antimicrobial Susceptibility Testing Market, by End User

  • Diagnostic Laboratories and Hospitals
  • Pharmaceutical and Biotechnology Companies
  • Research and Academic Institutes

Global Antimicrobial Susceptibility Testing Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
2.3.3. Growth Forecast
2.4. Assumptions for This Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Introduction
4.2. Drivers
4.2.1. High Prevalence of Infectious Diseases
4.2.2. Development of Automated and Manual AST Products
4.2.3. Emergence of Multidrug Resistance
4.2.4. Increased Funding and Government Initiatives
4.2.5. Technological Advancements towards the Development of Rapid AST Methods
4.3. Restraints
4.3.1. Stringent Government Regulations
4.4. Opportunities
4.4.1. Active R&D to Develop Rapid Antimicrobial Susceptibility Testing
4.4.2. Emerging Markets
4.5. Challenges
4.5.1. High Cost of Automated Antimicrobial Susceptibility Testing
4.5.2. Issues in AMR Surveillance in Low-Income and Middle-Income Countries
4.6. Covid-19 Impact Assessment
5. Antimicrobial Susceptibility Testing Market, by Product
5.1. Introduction
5.2. Manual Antimicrobial Susceptibility Testing Products
5.2.1. Susceptibility Disks
5.2.2. Susceptibility Plates
5.2.3. Minimum Inhibitory Concentration (MIC) Strips
5.3. Consumables
5.4. Automated Antimicrobial Susceptibility Testing Products
6. Global Antimicrobial Susceptibility Market, by Method
6.1. Introduction
6.2. Disk Diffusion
6.3. Automated Antimicrobial Susceptibility Testing
6.4. Dilution
6.5. Other Methods
7. Global Antimicrobial Susceptibility Testing Market, by Application
7.1. Introduction
7.2. Clinical Diagnostics
7.3. Drug Discovery and Development
7.4. Other Applications
8. Global Diagnostic Antibody Market, by End User
8.1. Introduction
8.2. Diagnostic Laboratories & Hospitals
8.3. Pharmaceutical & Biotechnology Companies
8.4. Research & Academic Institutes
9. Global Antimicrobial Susceptibility Testing Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. U.K.
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis
10.4.1. Biomérieux S.A. (France)
10.4.2. Thermo Fisher Scientific Inc. (U.S.)
10.4.3. Danaher Corporation (U.S.)
11. Company Profiles
11.1. Danaher Corporation
11.1.1. Business Overview
11.1.2. Financial Overview
11.1.3. Product Portfolio
11.1.4. Strategic Developments
11.2. Becton, Dickinson And Company
11.2.1. Business Overview
11.2.2. Financial Overview
11.2.3. Product Portfolio
11.2.4. Strategic Developments
11.3. Bio-Rad Laboratories, Inc.
11.3.1. Business Overview
11.3.2. Financial Overview
11.3.3. Product Portfolio
11.4. Thermo Fisher Scientific Inc.
11.4.1. Business Overview
11.4.2. Financial Overview
11.4.3. Product Portfolio
11.4.4. Strategic Developments
11.5. HiMedia Laboratories Pvt. Ltd.
11.5.1. Business Overview
11.5.2. Product Portfolio
11.6. Merlin Diagnostika GmbH
11.6.1. Business Overview
11.6.2. Financial Overview
11.6.3. Product Portfolio
11.6.4. Strategic Developments
11.7. bioMérieux S.A
11.7.1. Business Overview
11.7.2. Financial Overview
11.7.3. Product Portfolio
11.7.4. Strategic Developments
11.8. Merck KGaA
11.8.1. Business Overview
11.8.2. Financial Overview
11.8.3. Product Portfolio
11.9. Accelerate Diagnostics, Inc.
11.9.1. Business Overview
11.9.2. Financial Overview
11.9.3. Product Portfolio
11.9.4. Strategic Developments
11.10. Alifax S.r.l.
11.10.1. Business Overview
11.10.2. Product Portfolio
11.10.3. Strategic Developments
11.11. Creative Diagnostics
11.11.1. Business Overview
11.11.2. Product Portfolio
11.12. Synbiosis
11.12.1. Business Overview
11.12.2. Financial Overview
11.12.3. Product Portfolio
11.12.4. Strategic Developments
11.13. Zhuhai Dl Biotech Co., Ltd.
11.13.1. Business Overview
11.13.2. Product Portfolio
11.13.3. Strategic Developments
12. Appendix
12.1. Questionnaire
12.2. Available Customization

Samples

Loading
LOADING...

Companies Mentioned

Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMérieux S.A. (France), Becton, Dickinson and Company (U.S.), Danaher Corporation (U.S.), HiMedia Laboratories Pvt. Ltd. (India), MERLIN Diagnostika GmbH (Germany), Accelerate Diagnostics, Inc. (U.S.), Alifax S.r.l. (Italy), Creative Diagnostics (U.S.), Synbiosis (U.K.), and Zhuhai DL Biotech Co., Ltd (China).

Methodology

Loading
LOADING...

Table Information